174 related articles for article (PubMed ID: 24671452)
1. Downregulating sCLU enhances the sensitivity of hepatocellular carcinoma cells to gemcitabine by activating the intrinsic apoptosis pathway.
Xiu P; Xu Z; Liu F; Li Z; Li T; Zou F; Sun X; Li J
Dig Dis Sci; 2014 Aug; 59(8):1798-809. PubMed ID: 24671452
[TBL] [Abstract][Full Text] [Related]
2. Secretory clusterin contributes to oxaliplatin resistance by activating Akt pathway in hepatocellular carcinoma.
Xiu P; Dong X; Dong X; Xu Z; Zhu H; Liu F; Wei Z; Zhai B; Kanwar JR; Jiang H; Li J; Sun X
Cancer Sci; 2013 Mar; 104(3):375-82. PubMed ID: 23279642
[TBL] [Abstract][Full Text] [Related]
3. Secretory Clusterin Mediates Oxaliplatin Resistance via the Gadd45a/PI3K/Akt Signaling Pathway in Hepatocellular Carcinoma.
Wang X; Zou F; Zhong J; Yue L; Wang F; Wei H; Yang G; Jin T; Dong X; Li J; Xiu P
J Cancer; 2018; 9(8):1403-1413. PubMed ID: 29721050
[No Abstract] [Full Text] [Related]
4. Downregulation of secreted clusterin potentiates the lethality of sorafenib in hepatocellular carcinoma in association with the inhibition of ERK1/2 signals.
Zhong J; Yu X; Dong X; Lu H; Zhou W; Li L; Li Z; Sun P; Shi X
Int J Mol Med; 2018 May; 41(5):2893-2900. PubMed ID: 29436591
[TBL] [Abstract][Full Text] [Related]
5. Secretory Clusterin: A Promising Target for Chemoresistance of Hepatocellular Carcinoma.
Zhang J; Wu M; Xu Y; Song Q; Zheng W
Mini Rev Med Chem; 2020; 20(12):1153-1165. PubMed ID: 32228422
[TBL] [Abstract][Full Text] [Related]
6. sCLU as prognostic biomarker and therapeutic target in osteosarcoma.
Ma J; Gao W; Gao J
Bioengineered; 2019 Dec; 10(1):229-239. PubMed ID: 31117872
[TBL] [Abstract][Full Text] [Related]
7. Antisense oligonucleotide against clusterin regulates human hepatocellular carcinoma invasion through transcriptional regulation of matrix metalloproteinase-2 and E-cadherin.
Chen D; Wang Y; Zhang K; Jiao X; Yan B; Liang J
Int J Mol Sci; 2012; 13(8):10594-10607. PubMed ID: 22949882
[TBL] [Abstract][Full Text] [Related]
8. Secretory clusterin promotes hepatocellular carcinoma progression by facilitating cancer stem cell properties via AKT/GSK-3β/β-catenin axis.
Zheng W; Yao M; Wu M; Yang J; Yao D; Wang L
J Transl Med; 2020 Feb; 18(1):81. PubMed ID: 32059741
[TBL] [Abstract][Full Text] [Related]
9. Induction of clusterin by AKT--role in cytoprotection against docetaxel in prostate tumor cells.
Zhong B; Sallman DA; Gilvary DL; Pernazza D; Sahakian E; Fritz D; Cheng JQ; Trougakos I; Wei S; Djeu JY
Mol Cancer Ther; 2010 Jun; 9(6):1831-41. PubMed ID: 20501799
[TBL] [Abstract][Full Text] [Related]
10. Knockdown of clusterin sensitizes pancreatic cancer cells to gemcitabine chemotherapy by ERK1/2 inactivation.
Tang Y; Liu F; Zheng C; Sun S; Jiang Y
J Exp Clin Cancer Res; 2012 Sep; 31(1):73. PubMed ID: 22967941
[TBL] [Abstract][Full Text] [Related]
11. Nutlin-3 reverses the epithelial-mesenchymal transition in gemcitabine-resistant hepatocellular carcinoma cells.
Wu Q; Wang X; Liu J; Zheng J; Liu Y; Li Y; Su F; Ou W; Wang R
Oncol Rep; 2016 Sep; 36(3):1325-32. PubMed ID: 27430152
[TBL] [Abstract][Full Text] [Related]
12. [Down-regulated clusterin expression enhances sensitivity of hepatoma cells to anti-cancer drugs].
Zheng WJ; Sai WL; Yao M; Cai Y; Pan LH; Gu JJ; Wu W; Yao DF
Zhonghua Gan Zang Bing Za Zhi; 2015 Nov; 23(11):844-8. PubMed ID: 26743245
[TBL] [Abstract][Full Text] [Related]
13. Secretory Clusterin as a Novel Molecular-targeted Therapy for Inhibiting Hepatocellular Carcinoma Growth.
Yao M; Sai W; Zheng W; Wang L; Dong Z; Yao D
Curr Med Chem; 2020; 27(20):3290-3301. PubMed ID: 31232234
[TBL] [Abstract][Full Text] [Related]
14. Opsin3 sensitizes hepatocellular carcinoma cells to 5-fluorouracil treatment by regulating the apoptotic pathway.
Jiao J; Hong S; Zhang J; Ma L; Sun Y; Zhang D; Shen B; Zhu C
Cancer Lett; 2012 Jul; 320(1):96-103. PubMed ID: 22313545
[TBL] [Abstract][Full Text] [Related]
15. Tumor-derived secretory clusterin induces epithelial-mesenchymal transition and facilitates hepatocellular carcinoma metastasis.
Wang C; Jiang K; Kang X; Gao D; Sun C; Li Y; Sun L; Zhang S; Liu X; Wu W; Yang P; Guo K; Liu Y
Int J Biochem Cell Biol; 2012 Dec; 44(12):2308-20. PubMed ID: 23010347
[TBL] [Abstract][Full Text] [Related]
16. Clusterin silencing inhibits proliferation and reduces invasion in human laryngeal squamous carcinoma cells.
Wang Q; Cao W; Su Q; Liu Z; Zhang L
World J Surg Oncol; 2014 Apr; 12():124. PubMed ID: 24767179
[TBL] [Abstract][Full Text] [Related]
17. Silencing of secretory clusterin sensitizes NSCLC cells to V-ATPase inhibitors by downregulating survivin.
Kim YS; Jin HO; Hong SE; Song JY; Hwang CS; Park IC
Biochem Biophys Res Commun; 2018 Jan; 495(2):2004-2009. PubMed ID: 29253572
[TBL] [Abstract][Full Text] [Related]
18. Chemosensitization of gemcitabine-resistant human bladder cancer cell line both in vitro and in vivo using antisense oligonucleotide targeting the anti-apoptotic gene, clusterin.
Muramaki M; So A; Hayashi N; Sowery R; Miyake H; Fujisawa M; Gleave ME
BJU Int; 2009 Feb; 103(3):384-90. PubMed ID: 19007378
[TBL] [Abstract][Full Text] [Related]
19. ASPP2 enhances chemotherapeutic sensitivity through the down-regulation of XIAP expression in a p53 independent manner in hepatocellular carcinoma.
Yang T; Gao Y; Liu D; Wang Y; Wu J; Liu X; Shi Y; Chen D
Biochem Biophys Res Commun; 2019 Jan; 508(3):769-774. PubMed ID: 30528232
[TBL] [Abstract][Full Text] [Related]
20. Survivin-mediated therapeutic efficacy of gemcitabine through glucose-regulated protein 78 in hepatocellular carcinoma.
Hung CS; Lin SF; Liu HH; Kuo LJ; Li LT; Su HY; Liew PL; Lin FY; Wei PL; Liu DZ; Chang YJ
Ann Surg Oncol; 2012 Aug; 19(8):2744-52. PubMed ID: 22258814
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
